Patent
Methods for treating and preventing insulin resistance and related disorders
Andrew S. Greenberg
- 17 Oct 2000
36
TL;DR: In this article, the authors proposed a method for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolytic, and/or excessive free fatty acid levels.
read more
Abstract: The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a preferred embodiment, the method includes administering to a subject in need a pharmaceutically effective amount of an inhibitor of the JNK signal transduction pathway and/or an inhibitor of the MAPK/ERK signal transduction pathway.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Differentiation modulating agents and uses therefor
Johannes B. Prins,L Hutley,Ross P. McGeary +2 more
- 27 Jun 2003
TL;DR: In this paper, the authors present methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway for treating or preventing adiposity-related conditions including, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
47
Patent
Ppar (gamma) modulators
Yoshiya Amemiya,Kenji Wakabayashi,Sachiko Takaishi,Chie Fukuda +3 more
- 26 Apr 2001
TL;DR: In this paper, the PPARη modulators are used in remedies for involutional osteoporosis which inhibit the accelerated differentiation of adipocytes and promote the formation and differentiation of osteoblasts from stem cells, or remedies for diabetes which are free from excessive formation of adipocyte, liver functional failure, vascular lesion, heart failure, etc.
37
Patent
Methods for treating inflammatory conditions or inhibiting JNK
Brydon L. Bennett,Shripad S. Bhagwat,Anthony M. Manning,Brion W. Murray,Eoin C. O'leary,Yoshitaka Satoh +5 more
- 16 Dec 2003
TL;DR: In this article, a method for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone derivative having the following structure: Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined as defined herein.
24
Patent
Inhibition of jun kinase
Gökhan S. Hotamisligil,Michael Karin,Lufen Chang +2 more
- 24 Apr 2002
TL;DR: In this paper, a method of treating a metabolic disorder associated with insulin resistance by administering to a mammal an inhibitor of a NH2-terminal Jun Kinase (JNK), e.g., a compound or peptide which inhibits JNK1 expression or enzymatic activity.
22
Patent
Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto
Steven T. Sakata,Heather K. Raymon +1 more
- 22 Jun 2005
TL;DR: Isothiazoloanthrones, isooxazoloanthrone, isoindolanthrones, and derivatives thereof having the general formula: and pharmaceutically acceptable salts thereof, wherein R0 is CH2, CH2 or S 2 as mentioned in this paper.
22
References
Role of Insulin Resistance in Human Disease
TL;DR: The possibility is raised that resistance to insulin-stimulated glucose uptake and hyperinsulinemia are involved in the etiology and clinical course of three major related diseases— NIDDM, hypertension, and CAD.
13.2K
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
TL;DR: Experiments with guinea-pig lung suggest that some of the therapeutic effects of sodium salicylate and aspirin-like drugs are due to inhibition of the synthesis of prostaglandins.
8.8K
An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)
Jürgen M. Lehmann,Linda B. Moore,Tracey Smith-Oliver,William O. Wilkison,Timothy M. Willson,Steven A. Kliewer +5 more
TL;DR: It is reported that thiazolidinediones are potent and selective activators of peroxisome proliferator-activated receptor γ (PPARγ), a member of the nuclear receptor superfamily recently shown to function in adipogenesis, and raised the intriguing possibility that PPARγ is a target for the therapeutic actions of this class of compounds.
3.8K
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.
TL;DR: A role for the abnormal regulation of this cytokine in the pathogenesis of obesity-related insulin resistance is suggested as well as the effects of weight reduction by dietary treatment of obesity on the adipose expression of TNF-alpha mRNA.
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
Mercedes Ricote,Andrew C. Li,Andrew C. Li,Timothy M. Willson,Carolyn J. Kelly,Christopher K. Glass +5 more
TL;DR: It is shown that PPAR-γ is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ2 and synthetic PPar-γ ligands, suggesting that PPARS and locally produced prostaglandin D2 metabolites are involved in the regulation of inflammatory responses.
3.7K